PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Evergrande: just a wake call?

Fri, 24th Sep 2021 12:34

* European stock fall

* Wall Street futures lower

* Evergrande fears persist

* Yields march on higher

Sept 24 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

EVERGRANDE: JUST A WAKE-UP CALL? (1132 GMT)

There seems to be quite a strong consensus out there that
China's Evergrande doesn't pose a systemic risk for global
markets even if Monday's selloff is probably still on every
trader's mind.

For Amundi's CIOs, the worries surrounding a possible
default of the Chinese developer constitute a timely warning of
the risks facing markets.

"Evergrande is a wake-up call for investors and a reminder
of the highly leveraged sectors in the system, with valuations
at boiling point", Pascal Blanqué and Vincent Mortier wrote in a
note today where they lower their growth forecast for China.

But Blanqué and Mortier believe there's a much broader issue
for investors.

"We expect higher volatility in global markets in the coming
months and not only from China", they warn, pointing out to the
U.S. debt ceiling negotiations and Europe's issues with rising
energy prices.

It's time to adapt to a less positive environment they
argue.

"We believe that it is time to be neutral in terms of risk
allocation and increase scrutiny on those areas which could be
hit by spillover effects (e.g., Asian high-yield bonds,
construction-linked commodity prices)".

Here's Amundi new forecast for China:

(Julien Ponthus)

******

TINA IS STILL AROUND (1127 GMT)

Something tells us that the TINA (there is no alternative)
effect is still ready to fuel a buy-the-dip mentality.

In a research report Barclays analysts highlight that a
material selling in ETFs on risk-off Monday was followed by
significant inflows.

“So once again, the retail ‘army’ is showing animal
spirits,” according to Barclays analysts.

Looking at a broader picture, they say now the main
categories of investors are fully invested, “which means they
are in a position to sell if something goes wrong.”

“But investors also appear to be well hedged, with high skew
and put-call ratios both signalling significant protection in
place,” they add.

They call this positioning “cautiously long.”

(Stefano Rebaudo)

*****

YOU'RE NEVER(GRANDE) GONNA BELIEVE IT (0942 GMT)

The woes of debt-hobbled Evergrande must have slammed the
Chinese property sector shares this week, right?

Well not really!

As you can see below, many stocks are up on the week at the
exception of course of Sinic Holdings which was
suspended from trade on Monday.

Even more surprisingly, Evergrande itself has scored a
modest gain.

Maybe it's just some traders taking punts after the huge
crashes of the last few months - Evergrande is still down more
than 80% this year - but Beijing clearly wants to avoid a
complete implosion, so the question is, is it something to build
on?
Here's the same table year-to-date:

And here's some reading on the sector:

ANALYSIS-Chinese property debt issuers face 'Evergrande
premium' as worries mount

(Marc Jones)

*****

BANK STOCKS? FORGET CHINA, LOOK AT RATES (0935 GMT)

Higher rates expectations are supposed to boost European
bank stocks while China real estate concerns might present a
downside risk to the sector.

The big question is what between these two factors is going
to prevail.

Credit Suisse analysts see limited direct exposure to
China’s troubled Evergrande.

“Data collection from banks’ disclosures, and cross-check
with Bank of International Settlements (BIS) data on banks’
cross-border positions, suggests Mainland China and Hong Kong
lending by European banks is broadly quite limited,” they say.

JP Morgan does not expect meaningful exposure for European
banks, except for HSBC and Standard Chartered.
Its analysis of syndicated loans data available for major
property developers in China suggests “limited involvement.”

Credit Suisse analysts noted that during the 2014-15
slowdown, banks with more emerging markets balance sheet
exposure underperformed the STOXX 600 bank stock index.

Furthermore, episodes where U.S. 10-year rates rise more
than 50bp over 3 months on average “lead to a 10% rise in the
bank stock index.”

“SocGen, ING and Lloyds (all
rated Outperform by the team) have performed best on average
over three months during these rate episodes,” they add.

The chart below shows the STOXX 600 bank index and
U.S. 10-year Treasury yields and their correlation
(on 75-day data).

(Stefano Rebaudo and Anushka Trivedi)

*****

EUROPE'S SHARES SLIDE, BUT STILL SET FOR WEEKLY GAINS (0725
GMT)

European shares are falling amid concerns about the fate of
embattled property developer China Evergrande Group and a sudden
spike in bond yields. But after three days of strong
performance, the STOXX 600 is still set for weekly gains.

The top fallers this morning are sport clothing brands and
retailers Adidas, Puma and JD Sports
after rival Nike reported a Q4 results miss and cut its
FY 2022 sales expectations due to a supply chain crunch brought
in by months-long factory closures in Vietnam.

On a brighter note, shares in Astrazeneca rise
around 3% after the company reported positive results from the
PROpel Phase III trial.

(Joice Alves)

*****

MOVE OVER EVERGRANDE, TIME TO WATCH SOARING BOND YIELDS
(0705 GMT)

World markets remain on edge on Friday as simmering concerns
about the fate of embattled property developer China Evergrande
Group and a sudden spike in bond yields remind investors that
the final quarter of 2021 will be tricky to navigate.

European and U.S. stock futures fluctuated between gains and
losses after U.S. stocks posted their biggest two-day rise since
July.

While a large part of those gains can be attributed to
easing concerns about Evergrande contagion, Thursday's spike in
yields in the global $60 trillion plus government debt markets
raised the prospects of tighter monetary policy sooner than
later.

Long-term U.S. Treasury yields have surged the most in 18
months as traders brought forward expectations for the first Fed
rate hike to the end of 2022 and the Bank of England opened the
door to a 2021 rate increase -- sparking the biggest jump in
two-year UK gilt yields since March 2015.

Yield curves from Australia to Germany bear steepened in
response and the dollar sprung to the top of its 2021 trading
range. While it remains to be seen whether the rise in yields
can be sustained, some signs of weakness can be detected in the
“buy the dip” trade from investors.

Value stocks, a beneficiary of higher yields, outperformed
growth ones on Thursday while FAANG stocks have underperformed
broader markets so far this month. And if investors are hoping
quiet weekend, think again.

Sunday's election in powerhouse European economy Germany
will provide food for thought as Chancellor Angela Merkel steps
down after 16 years in charge.

Her successor will play a new role in shaping domestic and
broader EU policy and have to steer Germany's economy through a
still uncertain post-COVID environment.

Thursday's flash PMIs for September pointed to a sharp
slowdown in economic activity from the previous month from
rising energy prices and difficulty in sourcing parts and
materials, headwinds that are unlikely to abate in the coming
days.

Key developments that should provide more direction to
markets on Friday:

- ECB's Lagarde says many causes of inflation spike
temporary: CNBC

- Nike warns on holiday delays, cuts full-year sales
estimate

- Daimler's Mercedes-Benz to take a 33% stake in
battery cell manufacturer Automotive Cells Company

- Germany's IFO survey for September

- Fed speaker corner: Powell, Clarida

(Saikat Chatterjee)

*****

EUROPE SET FOR WEEKLY GAINS (0635 GMT)

Futures are pointing to a flat open for European bourses but
the STOXX 600 is set for strong weekly gains, with analysts
saying investors bought the dip this week after a sharp Monday
fall, amid uncertainty around the fate of debt-ridden China
Evergrande.

The risk on sentiment was also supported by a rate hike by
the Norwegian central bank and hawkish remarks from the Bank of
England reinforced market expectations that the Federal Reserve
would begin tapering by year end.

Capping the enthusiasm, property developer Evergrande missed
an interest payment deadline on Thursday and has entered a
30-day grace period.

(Joice Alves)

*****

More News
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.